Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 394
- Registration Number
- NCT00600626
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 242
- Registration Number
- NCT00598793
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States
Human Insulin NPH and Insulin Aspart in Type 1 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 91
- Registration Number
- NCT00597233
- Locations
- 🇦🇷
Novo Nordisk Investigational Site, Junin, Argentina
Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 114
- Registration Number
- NCT00595374
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Zwolle, Netherlands
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 220
- Registration Number
- NCT00593255
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 164
- Registration Number
- NCT00592969
- Locations
- 🇧🇷
Novo Nordisk Investigational Site, Santa Efigenia, Brazil
Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 132
- Registration Number
- NCT00592527
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Nagpur, India
Initiation of Insulin Aspart in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00572806
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT00571935
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00571584
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath